Neutrophil production

"Neutrophil production" refers to the process by which new neutrophils are generated from hematopoietic stem cells in the bone marrow—a process known as granulopoiesis. This involves tightly regulated steps including proliferation, differentiation, maturation, and release into circulation. Key molecular regulators include cytokines such as G-CSF; chemokines like CXCL12 and its receptor CXCR4; transcription factors such as C/EBP family members; and feedback signals from senescent cell clearance. Disruption at any stage can result in clinical conditions ranging from immunodeficiency due to low counts (neutropenia) to excessive inflammation if overproduced. While "neutrophil production" itself is not a druggable target but rather a physiological process, several molecules involved in this pathway—such as G-CSF receptor—are established therapeutic targets for modulating blood neutrophil levels[1][2]. Note: "Neutrophil production" does not refer to a specific molecule or receptor but rather describes an essential biological process involving multiple molecular targets. For structured data on druggable entities within this pathway, focus should be placed on individual proteins such as "Granulocyte colony-stimulating factor receptor," "CXCR4," etc.[1][2].

Other names

granulopoiesisneutrophil granulopoiesis

Drugs like G-CSF act by stimulating the proliferation and differentiation of myeloid progenitor cells into mature neutrophils, primarily through modulation of chemokine expression in the bone marrow microenvironment[1].